Capstone Investment Advisors
APLS

Capstone Investment Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Capstone Investment Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-250,000
Closed -$10.1M – 1663
2026
Q1 		$10.1M Buy
+250,000
New +$5.39M 0.02% 281
2025
Q4 		– Sell
-21,371
Closed -$484K – 1572
2025
Q3 		$484K Buy
21,371
+9,671
+83% +$226K ﹤0.01% 1397
2025
Q2 		$203K Buy
+11,700
New +$217K ﹤0.01% 1531

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Capstone Investment Advisors's APLS Position: Q2 2026 in Review

Capstone Investment Advisors sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 250,000 shares — an estimated $10.1M sold.

Capstone Investment Advisors first reported a position in APLS in Q2 2025 and held it in 3 quarters. The position peaked at $10.1M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Capstone Investment Advisors reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Capstone Investment Advisors sold 250,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $10.1M.
  • Capstone Investment Advisors first reported a position in Apellis Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Capstone Investment Advisors's Apellis Pharmaceuticals position peaked at $10.1M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.